[1. Chan ST, Ou JJ. Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response. Viruses. 2017;9(8):224.10.3390/v9080224558048128805674]Search in Google Scholar
[2. Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018;24(47):5297-5311.10.3748/wjg.v24.i47.5297630553030598575]Search in Google Scholar
[3. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host – Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4):376.10.3390/cells8040376652373431027278]Search in Google Scholar
[4. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and Management of Hepatitis C. Am Fam Physician. 2015;91(12):835-842.]Search in Google Scholar
[5. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.10.7150/ijms.3.47]Search in Google Scholar
[6. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.10.1038/nrdp.2017.628252637]Search in Google Scholar
[7. Coppola N, Alessio L, Onorato L, et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty. 2019;8(1):17.10.1186/s40249-019-0528-6641937030871599]Search in Google Scholar
[8. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20(29):9633-9652.10.3748/wjg.v20.i29.9633412335525110404]Search in Google Scholar
[9. Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J. 2018;15(1):180.10.1186/s12985-018-1094-4625114330466446]Search in Google Scholar
[10. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91-133.10.3109/1040841090335745520345213]Search in Google Scholar
[11. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:42-47.10.1111/j.1365-2893.2011.01523.x22233413]Search in Google Scholar
[12. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593.10.1001/jama.2012.14487823268517]Search in Google Scholar
[13. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain?. Hepatology. 2014;59(6):2403-2412.10.1002/hep.2690524155107]Search in Google Scholar
[14. Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172-182.10.14218/JCTH.2018.00049660984431293918]Search in Google Scholar
[15. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75(15):7059-7066.10.1128/JVI.75.15.7059-7066.200111443411435586]Search in Google Scholar
[16. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61(1 Suppl):S14-S25.10.1016/j.jhep.2014.06.03525443342]Search in Google Scholar
[17. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-S68.10.1016/j.jhep.2014.07.01225443346]Search in Google Scholar
[18. Kinchen VJ, Bailey JR. Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol. 2018;9:1703.10.3389/fimmu.2018.01703608292330116237]Search in Google Scholar
[19. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host – Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4):376.10.3390/cells8040376652373431027278]Search in Google Scholar
[20. Baskic D, Vukovic V, Popovic S, et al. Correction: Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS One. 2019;14(8):e0221142.10.1371/journal.pone.0221142668716431393958]Search in Google Scholar
[21. Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells. 2019;8(10):1249.10.3390/cells8101249682958631615075]Search in Google Scholar
[22. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. Curr Pathobiol Rep. 2013;1(3):209-214.10.1007/s40139-013-0018-7375725224000319]Search in Google Scholar
[23. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond). 2007;112(3):141-155.10.1042/CS2006017117199558]Search in Google Scholar
[24. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724-732.10.1001/jama.297.7.72417312292]Search in Google Scholar
[25. Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch Med Wewn. 2008;118(12):734-740.10.20452/pamw.542]Search in Google Scholar
[26. Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol. 2018;10(2):186-212.10.4254/wjh.v10.i2.186583843929527256]Search in Google Scholar
[27. Dias C, Pipa S, Mota M. Acute hepatitis C from heterosexual transmission. IDCases. 2018;14:e00448.10.1016/j.idcr.2018.e00448612576130191131]Search in Google Scholar
[28. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem [published correction appears in Hepatology. 2008 Feb;47(2):769]. Hepatology. 2008;47(1):321-331.10.1002/hep.21902227749618161707]Search in Google Scholar
[29. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Metaanalysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016;150(7):1599-1608.10.1053/j.gastro.2016.02.03926924097]Search in Google Scholar
[30. Sayiner M, Golabi P, Farhat F, Younossi ZM. Dermatologic Manifestations of Chronic Hepatitis C Infection. Clin Liver Dis. 2017;21(3):555-564.10.1016/j.cld.2017.03.01028689593]Search in Google Scholar
[31. Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis. 2017;21(3):455-464.10.1016/j.cld.2017.03.00228689585]Search in Google Scholar
[32. Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017;21(3):465-473.10.1016/j.cld.2017.03.00328689586]Search in Google Scholar
[33. Mapoure NY, Budzi MN, Eloumou SAFB, Malongue A, Okalla C, Luma HN. Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS One. 2018;13(3):e0192406.10.1371/journal.pone.0192406584165529513678]Search in Google Scholar
[34. Couronné L, Bachy E, Roulland S, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol. 2018;29(1):92-100.10.1093/annonc/mdx63529045541]Search in Google Scholar
[35. Flores-Chávez A, Carrion JA, Forns X, Ramos-Casals M. Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. Rev Esp Sanid Penit. 2017;19(3):87-97.]Search in Google Scholar
[36. Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29.10.1186/s13027-016-0076-7487804027222662]Search in Google Scholar
[37. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014;20(24):7544-7554.10.3748/wjg.v20.i24.7544406928624976695]Search in Google Scholar
[38. Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018;67(2):492-504.10.1002/hep.29505581473028873225]Search in Google Scholar
[39. Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33(4):551-557.10.1007/s11606-017-4280-y588077129352420]Search in Google Scholar
[40. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401-412.10.1016/j.bpg.2012.09.00923199500]Search in Google Scholar
[41. Karnsakul W, Schwarz KB. Hepatitis B and C. Pediatr Clin North Am. 2017;64(3):641-658.10.1016/j.pcl.2017.01.007543326228502443]Search in Google Scholar
[42. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16(2):75-90.10.1111/j.1365-2893.2008.01012.x275998718761607]Search in Google Scholar
[43. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421-1432.10.3748/wjg.v22.i4.1421472197726819511]Search in Google Scholar
[44. Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci. 2017;19(1):23.10.3390/ijms19010023579597429271914]Search in Google Scholar
[45. Simonović Babić J, Bojović K, Fabri M, Cvejić T, Svorcan P, Noţić D, Jovanović M, Škrbić R, Stojiljković MP, Mijailović Ţ. A real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with genotype 1 chronic hepatitis C virus infection in Serbia. Vojnosanit Pregl. 2019; 76(5): 531–536.10.2298/VSP170727186S]Search in Google Scholar
[46. Kim S, Han KH, Ahn SH. Hepatitis C Virus and Antiviral Drug Resistance. Gut Liver. 2016;10(6):890-895.10.5009/gnl15573508792727784846]Search in Google Scholar
[47. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535-542.10.1038/nri346323743475]Search in Google Scholar
[48. Bojovic K, Simonovic-Babic J, Mijailovic Z, et al. Micro- elimination of HCV as a possible therapeutic strategy: our experience and a review of literature. J Infect Dev Ctries. 2020;14(2):117-124.10.3855/jidc.1178532146444]Search in Google Scholar
[49. Akchurin OM. Chronic Kidney Disease and Dietary Measures to Improve Outcomes. Pediatr Clin North Am. 2019;66(1):247-267.10.1016/j.pcl.2018.09.007662397330454747]Search in Google Scholar
[50. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329-vii.10.1016/j.pop.2008.01.008247478618486718]Search in Google Scholar
[51. Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(suppl_3):iii35-iii40.10.1093/ndt/gfy175616880130281126]Search in Google Scholar
[52. Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016;7:21-32.10.2147/POR.S97310508776627822135]Search in Google Scholar
[53. Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease [published correction appears in Clin Exp Nephrol. 2019 Mar 2;:]. Clin Exp Nephrol. 2019;23(4):437-447.10.1007/s10157-018-1641-8643562630178234]Search in Google Scholar
[54. Razmaria AA. Chronic Kidney Disease. JAMA. 2016;315(20):2248.10.1001/jama.2016.142627218648]Search in Google Scholar
[55. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238-1252.10.1016/S0140-6736(16)32064-5]Search in Google Scholar
[56. Breyer MD, Susztak K. Developing Treatments for Chronic Kidney Disease in the 21st Century. Semin Nephrol. 2016;36(6):436-447.10.1016/j.semnephrol.2016.08.001542340427987541]Search in Google Scholar
[57. Petrović D, Miloradović V, Poskurica M, Stojimirović B. Srp Arh Celok Lek. 2011;139(3-4):248-255.10.2298/SARH1104248P]Search in Google Scholar
[58. Lee WC, Lee YT, Li LC, et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3–5 Chronic Kidney Disease. J Clin Med. 2018;7(12):493.10.3390/jcm7120493630690630486496]Search in Google Scholar
[59. Reichel H, Zee J, Tu C, et al. Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2020;35(5):803-810.10.1093/ndt/gfz260720356031953939]Search in Google Scholar
[60. Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease. Hemodial Int. 2018;22(3):297-307.10.1111/hdi.1267230141571]Search in Google Scholar
[61. Lukic R, Gajovic N, Jovanovic I, Jurisevic M, Mijailovic Z, Maric V, Popovska Jovicic B, Arsenijevic N. Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients. Disease Markers olume 2017; 2017:Article ID 627598710.1155/2017/6275987540556928487598]Search in Google Scholar
[62. Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol. 2015;7(1):78-92.10.4254/wjh.v7.i1.78429519725624999]Search in Google Scholar
[63. Caragea DC, Mihailovici AR, Streba CT, et al. Hepatitis C Infection in Hemodialysis Patients. Curr Health Sci J. 2018;44(2):107-112.]Search in Google Scholar
[64. Lukic R, Cupic M, Gajovic N, et al. Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection. J Infect Dev Ctries. 2020;14(5):519-526.10.3855/jidc.1174132525839]Search in Google Scholar
[65. Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-134.10.1111/sdi.12761641105530569604]Search in Google Scholar
[66. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. J Hepatol. 2016;65(1 Suppl):S82-S94.10.1016/j.jhep.2016.06.01127641990]Search in Google Scholar
[67. Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2019;32(2):108-118.10.1111/sdi.12759641072830496620]Search in Google Scholar